RxDoctor Payments Data

Baljit Sappal, MD

Internal Medicine · Elizabeth, NJNPI 1124054747

Payments from drug & device makers

$921in general payments, 2019–2025

Across 63 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$262
  • Novo Nordisk$137
  • GSK$95
  • Amgen$87
  • Sanofi-aventis U.S. LLC$84
  • Merck$72
  • plus $184 from 8 others

What the payments were for

  • Food & beverage$921100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$921 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$61,033
Medicare patients
57
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$52,821
JanuviaSitagliptin Phosphate59$45,425
OzempicSemaglutide19$21,247
Bydureon BciseExenatide Microspheres16$19,043
FarxigaDapagliflozin Propanediol18$17,076
MounjaroTirzepatide16$16,462
EliquisApixaban22$14,695
JanumetSitagliptin Phos/Metformin Hcl22$14,236
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,142
XareltoRivaroxaban21$11,385
Tresiba Flextouch U-100Insulin Degludec21$9,939
TradjentaLinagliptin13$7,295
Tresiba Flextouch U-200Insulin Degludec11$7,023
Praluent PenAlirocumab11$6,733
Atorvastatin Calcium407$3,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$72$59,66181 claims
AstraZenecaFarxiga, Breztri Aerosphere$262$30,21839 claims
Novo NordiskOzempic$137$21,24719 claims
Lilly USA, LLCMounjaro$44$16,46216 claims
PfizerEliquis$17$14,69522 claims
Johnson & JohnsonXarelto$14$11,38521 claims
GSKShingrix$95$2,97215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Elizabeth

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →